Sun Pharma Advanced Research Company Limited has informed the Exchange regarding 'Statutory Auditor's Certificate in terms of Regulation 169(5) of SEBI ICDR Regulations'.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma Advanced Research Company (SPARC) submitted a statutory auditor's certificate (from S R B C & Co LLP) confirming compliance with Regulation 169(4) of the SEBI ICDR Regulations. The filing also includes a statement of receipt for Rs. 149.99 crore (approximately Rs. 150 crore) received from Shanghvi Finance Private Limited as consideration for 3,85,10,000 (38.51 million) warrants allotted under a preferential issue under Chapter V of SEBI ICDR Regulations, 2018. The funds were received on May 19, 2026 via four UTR transactions through ICICI Bank.
The receipt of warrant consideration confirms completion of fund inflow for a large preferential warrant allotment to a related entity (Shanghvi Finance is connected to the promoters). This is a routine regulatory compliance filing confirming ICDR compliance, with no immediate direct impact on the stock, but confirms capital raising activity.